Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)

Sponsor: Queen Mary University of London

NCT ID: NCT07165678

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
CTCA (diagnostic test)
How long the study runs
Study runs about 39 months (dates as stated)
About the drug or intervention
CTCA — diagnostic test: Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years and over
Who
All
Number of participants
1,000
Started
2026-04-16
Last checked
2026-06

Plain English Summary

What is this study?

  • • Testing a new treatment for coronary heart disease
  • • NA - 1,000 participants
  • • The goal of this clinical trial is to evaluate whether a coronary computed tomography angiography (CTCA)-guided strategy can reduce the risk of death, heart attack, stroke, and hospital admissions in patients experiencing angina or myocardial infarction following coronary artery bypass graft (CABG) surgery

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with coronary heart disease

Where?

  • • London - St Bartholomew's Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The goal of this clinical trial is to evaluate whether a coronary computed tomography angiography (CTCA)-guided strategy can reduce the risk of death, heart attack, stroke, and hospital admissions in patients experiencing angina or myocardial infarction following coronary artery bypass graft (CABG) surgery. The main questions it aims to answer are: * Can CTCA reduce major adverse cardiovascular events compared to standard invasive coronary angiography? * Is CTCA a cost-effective and safer alternative that improves patient quality of life? Researchers will compare outcomes between patients receiving CTCA prior to angiography and those undergoing standard angiography alone to determine if CTCA improves clinical outcomes and procedural safety. Participants will: * Be randomly assigned to either CTCA-guided care or standard angiography * Undergo coronary imaging and follow-up assessments * Complete questionnaires on quality of life and healthcare resource use

More detail

Patients with prior coronary artery bypass graft (CABG) surgery frequently present with recurrent angina or acute coronary syndromes due to progressive native coronary artery disease or graft failure. Invasive coronary angiography remains the standard diagnostic approach but is technically challenging in this population due to variable graft anatomy, leading to prolonged procedure times, increased radiation exposure, higher contrast volumes, and elevated risk of procedural complications. Computed Tomography Coronary Angiography (CTCA) offers a non-invasive alternative with high diagnostic accuracy for graft patency and coronary anatomy. Prior observational data (e.g., BYPASS-CTCA study) suggest that CTCA performed prior to invasive angiography may improve procedural efficiency and safety. However, whether CTCA can guide clinical decision-making to avoid unnecessary angiography and improve long-term outcomes remains unproven. This multi centre, randomised controlled trial will enrol 1,000 patients with prior CABG presenting with angina or myocardial infarction. Participants will be randomised to either a CTCA-guided strategy or standard care involving direct invasive coronary angiography. In the CTCA arm, angiography may be deferred if CTCA findings support medical management. The primary outcome is the composite rate of major adverse cardiovascular events (MACE), including death, myocardial infarction, stroke, and hospitalisation for unstable angina. Secondary outcomes include procedural metrics, patient-reported quality of life, cost-effectiveness, and healthcare resource utilization. Clinical data will be collected through patient questionnaires, procedural records, and central registry downloads. The study incorporates patient and public involvement throughout its design and implementation. Results will be disseminated via peer-reviewed publications, public-facing reports, and digital platforms.

Coronary Heart Disease

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

What the study is looking for

  • ✓Aged ≥18
  • ✓Previous coronary artery bypass grafting (CABG)
  • ✓An indication for coronary angiography
  • ✓Angina
  • ✓Ischaemia on perfusion imaging

Who cannot take part

  • ✗Subjects presenting with ST segment myocardial infarction within window for primary PCI
  • ✗Patients considered unsuitable to participate by the research team (e.g. due to medical reasons, laboratory...
  • ✗Life expectancy less than 1 year
See the full criteria
Inclusion Criteria: * Aged ≥18 * Previous coronary artery bypass grafting (CABG) * An indication for coronary angiography * Angina * Ischaemia on perfusion imaging * Acute coronary syndrome * Patients are able and willing to give their written informed consent Exclusion Criteria: * Subjects presenting with ST segment myocardial infarction within window for primary PCI * Patients considered unsuitable to participate by the research team (e.g. due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures) * Life expectancy less than 1 year

Where Is This Study? (1 UK site)

St Bartholomew's Hospital

London, United Kingdom

Recruiting
Site contact (verified)
Krishna Rathod02037658707

How to Get in Touch

Mervyn Andiapen

Sponsor contact

CONTACT

0203 765 8707 mervyn.andiapen@nhs.net

Matthew Kelham, MBBS, MD

Sponsor contact

CONTACT

m.kelham@nhs.net
Data sourced from ClinicalTrials.gov · Last verified: 2026-06